AbbVie Inc. (ABBV)

90.54
0.16 0.18
NYSE : Health Technology
Prev Close 90.70
Open 90.97
Day Low/High 90.25 / 91.70
52 Wk Low/High 62.55 / 97.86
Volume 3.23M
Avg Volume 13.29M
Exchange NYSE
Shares Outstanding 1.76B
Market Cap 163.32B
EPS 5.30
P/E Ratio 16.34
Div & Yield 4.72 (5.00%)
The Reasons to Be in AbbVie: Valuation, Dividend Yield, Confidence in Guidance

The Reasons to Be in AbbVie: Valuation, Dividend Yield, Confidence in Guidance

I have always liked the aggressive management.

The Charts of AbbVie Can Reach New Heights

The Charts of AbbVie Can Reach New Heights

A lifting on the moratorium on elective procedures could be a big win for ABBV.

Jim Cramer: This Opening Is the Beginning of the End of the Healthcare Recession

Jim Cramer: This Opening Is the Beginning of the End of the Healthcare Recession

What's really driving the market, what's making the Nasdaq roar? Tech and science, that's what.

Markets Test Support Levels, Amazon Earnings, Calibrating for Covid-19

Markets Test Support Levels, Amazon Earnings, Calibrating for Covid-19

The market sold off on Thursday after close as big hitters, including Amazon, reported earnings.

Jim Cramer: I Don't Think Covid-19 Is Invincible

Jim Cramer: I Don't Think Covid-19 Is Invincible

When it's beaten you will wish you own stocks, especially the stocks that are right now lethal to your portfolio.

A New Technical Strategy for AbbVie

A New Technical Strategy for AbbVie

Let's check out the charts of ABBV.

Jim Cramer: Finding Any Stocks With No Hair?

Jim Cramer: Finding Any Stocks With No Hair?

After a company reports we all know what's wrong, it's immunized. And that's when you can buy.

This Health Care Dividend King Offers a Remedy for Hopeless Investors

This Health Care Dividend King Offers a Remedy for Hopeless Investors

JNJ should survive a recession and prove in demand in a health crisis.

These Are the Times We Live In

These Are the Times We Live In

Here again is my approach and my three stock groups: 'rebound', 'revenue' and 'virus'.

Jim Cramer: Panicking Never Made Anyone a Dime, but These Will

Jim Cramer: Panicking Never Made Anyone a Dime, but These Will

Here are six companies that should come through in the tough times ahead.

Jim Cramer: Let's See Who's Safe, Who Isn't

Jim Cramer: Let's See Who's Safe, Who Isn't

You can use these wild market swings to your advantage by identifying 'safe' companies you want to own and then buying their stocks in stages.

Jim Cramer: Rate Cut No Cure for Coronavirus

Jim Cramer: Rate Cut No Cure for Coronavirus

But don't throw up your arms yet -- here are names that could be golden opportunities.

Jim Cramer: I Don't Know Where It Will Bottom, I Do Know What to Buy and Sell

Jim Cramer: I Don't Know Where It Will Bottom, I Do Know What to Buy and Sell

This is the time to high grade your portfolio, take some losses and move to better stocks.

AbbVie Could Be One of the Stocks That Recovers Before Others

AbbVie Could Be One of the Stocks That Recovers Before Others

Let's review the charts and indicators.

Three Strategies for Income Investors

Three Strategies for Income Investors

For reliable income, a portfolio strategy generating monthly payouts, an opportunity in dividend kings, and favorites among taxable bond funds.

Coronavirus Spreads, Reducing 'Big Oil', 4 Stocks to Watch, Adding Store Capital

Coronavirus Spreads, Reducing 'Big Oil', 4 Stocks to Watch, Adding Store Capital

Newly confirmed cases of the Covid-19 virus spiked from Hubei Province in China, where the city of Wuhan is located. The number of related deaths increased as well.

Tech Based Rally, Real-Life Virus, Powell Speaks, Tracking 5 Stocks

Tech Based Rally, Real-Life Virus, Powell Speaks, Tracking 5 Stocks

This rally has been industry, not sector led, and it is all based on technology, whether or not market leaders reside within the Tech sector or not.

Watch These Biotech Names on Strong Earnings

Watch These Biotech Names on Strong Earnings

Merger activity is the number 1 driver I am watching for biotech growth.

Coronavirus at Sea, Mahalanobis Distance, Trading 3 Stocks: Market Recon

Coronavirus at Sea, Mahalanobis Distance, Trading 3 Stocks: Market Recon

I'm watching the shares of Estee Lauder, Disney and Amazon.

Decisions, Decisions: AbbVie or Bristol-Myers Squibb?

Decisions, Decisions: AbbVie or Bristol-Myers Squibb?

AbbVie's weekly chart indicates its stock has room to run long term, but its daily chart suggests a rally in its shares is not imminent.

Jim Cramer: Panic Has Not Been Contained in This Market

Jim Cramer: Panic Has Not Been Contained in This Market

I think, ultimately, the big issue for many will be what happens in the United States if we hear about people who didn't go to China who have come down with the disease.

Why AbbVie Looks Like a Bargain at These Levels

Why AbbVie Looks Like a Bargain at These Levels

Nobody in AbbVie right now is in it for the past performance.

A Technical Strategy for AbbVie as the Broader Market Gets Rocked

A Technical Strategy for AbbVie as the Broader Market Gets Rocked

ABBV could bounce today but there remains the risk of a deeper correction.

Coronavirus Is Now a Market Story, Watching the U.S. 10 Year Note, Kobe Bryant

Coronavirus Is Now a Market Story, Watching the U.S. 10 Year Note, Kobe Bryant

Chinese President Xi Jinping, not a man given to exaggerate, has referred to the spread of this coronavirus in China as 'a grave situation.'

Jim Cramer: 6 Stocks to Buy on Coronavirus Fears

Jim Cramer: 6 Stocks to Buy on Coronavirus Fears

These companies all could be strong -- even if the 2019 nCoV fear spreads.

4 Favorite Biotech Stock Picks for 2020

4 Favorite Biotech Stock Picks for 2020

The Medical Technology Stock Letter's top pick rose 357% in 2019.

Jim Cramer: Don't Get Sacked in This Political Football Match

Jim Cramer: Don't Get Sacked in This Political Football Match

How to prepare your portfolio and be opportunistic in the face of this geopolitical instability.

This Dividend Aristocrat Is Our Top Pick for 2020

This Dividend Aristocrat Is Our Top Pick for 2020

As it smooths out the wrinkles from 2019, this pharmaceutical manufacturer should have a healthy year.

My Pick for 2020? You Won't Believe It's Been on Your Screen All Along

My Pick for 2020? You Won't Believe It's Been on Your Screen All Along

This company made headlines in 2019, and I'm betting on it as a great play -- in many senses of the word -- for this new year.